Affordable Access

[Orphan diseases: evaluations of new treatments].

Authors
Type
Published Article
Journal
La Revue de Médecine Interne
0248-8663
Publisher
Elsevier
Publication Date
Volume
28 Suppl 2
Identifiers
PMID: 18228689
Source
Medline

Abstract

The new treatments of orphan diseases must be assessed according to the methodologic rules of therapeutic trials, in order to ensure clinically and statistically significant evaluations: randomized controled trials, single primary end-point, statistically significant and clinically relevant efficience. Although these rules may be relaxed in orphan diseases, they have to maintain the standard of therapeutic efficiency.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments